DBV Technologies (NASDAQ:DBVT) Shares Pass Above Fifty Day Moving Average – Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $18.47 and traded as high as $23.53. DBV Technologies shares last traded at $21.61, with a volume of 395,621 shares changing hands.

Analyst Ratings Changes

DBVT has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research note on Thursday, December 18th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Guggenheim reissued a “buy” rating and issued a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.38.

DBV Technologies Stock Performance

The company has a market capitalization of $867.86 million, a price-to-earnings ratio of -4.18 and a beta of -1.17. The firm’s 50 day simple moving average is $18.47 and its 200-day simple moving average is $13.96.

Insiders Place Their Bets

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares in the company, valued at $41,688,039.20. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.44% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DBVT. New York State Common Retirement Fund purchased a new stake in DBV Technologies in the 3rd quarter worth approximately $34,000. GAMMA Investing LLC increased its stake in shares of DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of DBV Technologies during the third quarter worth $167,000. Citadel Advisors LLC acquired a new stake in DBV Technologies during the third quarter valued at $220,000. Finally, DLD Asset Management LP purchased a new position in DBV Technologies in the third quarter valued at about $250,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.